Bristol Myers' Relatlimab/Opdivo Combo Therapy Tops Opdivo Alone in Untreated Melanoma Patients

Bristol Myers Squibb Co BMY announced detailed results from the Phase 2/3 RELATIVITY-047 trial evaluating a fixed-dose combination of relatlimab and Opdivo (nivolumab) in untreated metastatic or unresectable melanoma patients.
The data will be presented at the 2021 ASCO in June.
A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1 blocker Opdivo (nivolumab) posted a progression-free survival of 10.12 months compared with 4.63 months for patients on Opdivo alone.
No new safety concerns for the combo were flagged, but the side effects were more severe than on Opdivo alone.
Severe/life-threatening drug-related side effects occurred in 18.9% of patients in the combo arm compared with 9.7% in the Opdivo arm.
Side effects leading to discontinuation occurred in 14.6% of patients on the combo, compared with 6.7% on Opdivo.
The company released topline data for the relatlimab/Opdivo combo in March, demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit compared to Opdivo (nivolumab) alone.
Price Action: BMY shares are up 1.86% at $66.78 during the market session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar